Tandem Diabetes Care, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Tandem Diabetes Care, Inc.
In an interview with Medtech Insight following the J.P. Morgan Health Care Conference, Dexcom CEO Kevin Sayer discussed marketing plans for the next-generation G7 continuous glucose monitoring system and for the simpler CGM, Dexcom One, and outlined plans ahead.
Dexcom is making CGM data available through consumer devices starting with Garmin’s smartwatches and bicycle computers.
In an interview with Medtech Insight, Dexcom CEO Kevin Sayer discussed his views on the blood glucose measurement market, how he thinks it will change, and Dexcom’s responsibilities to patients, regulators and payors.
The market for blood glucose monitoring devices is expected to see double-digit growth, reaching $19.7bn by 2025. This growth is driven largely by the rising demand for smaller, more convenient continuous glucose monitoring (CGMs) devices with improved digital capabilities.
- Drug Delivery
- Monitoring Equipment & Devices
Surgical Equipment & Devices
- Minimally or Less Invasive
In Vitro Diagnostics
- Glucose Testing